GRIFOLS (4GRF)

Overview

Grifols, S.A. is a prominent plasma therapeutic company based in Barcelona, Spain, with operations extending across Spain, the United States, Canada, and other international markets. Founded in 1909, the company stands as a leader in the development and distribution of essential plasma-derived therapeutic products aimed at treating a diverse range of medical conditions. Grifols is dedicated to advancing healthcare through its innovative solutions, including immunoglobulins, albumins, clotting factors, and a range of other biopharmaceuticals. In addition to its therapeutic offerings, Grifols provides diagnostic testing equipment and reagents, manufactures plasma for third parties, and is actively engaged in research and development to expand its portfolio of pharmaceutical products. With a strong foundation in plasma science, Grifols is committed to meeting the complex needs of patients globally through excellence in healthcare innovation.

Products and Services

• Immunoglobulin

Designed to treat immunodeficiencies, this product delivers critical support for individuals with compromised immune systems by enhancing their ability to fight infections.

• Albumin

Used in restoring circulatory volume and compensating for protein loss in various conditions including liver cirrhosis, cardiocirculatory failure, trauma, and severe burns.

• Alpha-1 Proteinase Inhibitor

Treats alpha-1 antitrypsin deficiency, a genetic disorder, helping to prevent lung tissue breakdown and maintain normal lung function.

• Clotting Factors (Factor VIII/Von Willebrand Factor and Factor IX)

They are essential for the treatment of hemophilia A, von Willebrand's disease, and hemophilia B, assisting in blood clotting for individuals with these conditions.

• Antithrombin III

Used to manage hereditary antithrombin deficiency, which poses risks of abnormal blood clots, promoting a healthier blood flow.

• Fostamatinib

A spleen tyrosine kinase inhibitor that addresses auto-immune disorders, offering new hope in the treatment of these conditions.

• Biological Sealants

Includes a combination of fibrinogen and thrombin, acting as a biological adhesive to control bleeding during surgical procedures.

• Plasma Exchange with Albumin for Alzheimer's Disease

This innovative treatment involves the use of plasma exchange with albumin to potentially slow or treat the progression of Alzheimer's disease.

• Diagnostic Testing Equipment and Reagents

Grifols markets a wide range of diagnostic equipment and reagents, enhancing the ability of healthcare providers to diagnose and monitor various medical conditions effectively.

• Yimmugo PID and Yimmugo ITP

These drugs represent Grifols' foray into immunology and hematology, addressing primary immunodeficiencies and immune thrombocytopenia, respectively.

• Research and Development Activities

Engaged in ongoing R&D efforts, Grifols is actively developing a pipeline of innovative therapies, including Xembify Pre-filled syringes, FlexBag, and Prolastin vials in Phase IV, alongside other promising treatments in various stages of clinical development.

• Collaborations

Grifols maintains strategic partnerships, including agreements with Canadian Blood Services, GIANT, and GigaGen, to develop recombinant polyclonal immunoglobulin therapies and to advance the processing of plasma-derived products.